Intellia Therapeutics’ (NTLA) “Neutral” Rating Reaffirmed at Wedbush

Wedbush reiterated their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Monday morning,RTT News reports. They currently have a $7.00 price target on the stock.

NTLA has been the topic of several other research reports. Wall Street Zen raised Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Citigroup dropped their target price on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Wells Fargo & Company dropped their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Intellia Therapeutics in a report on Monday. Finally, Canaccord Genuity Group dropped their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a report on Tuesday, June 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.95.

Intellia Therapeutics Trading Up 7.8%

NTLA opened at $8.96 on Monday. The business’s 50 day moving average is $8.14 and its 200-day moving average is $9.74. The stock has a market cap of $928.10 million, a PE ratio of -1.65 and a beta of 2.14. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. The business’s quarterly revenue was down 42.6% on a year-over-year basis. During the same period last year, the firm posted ($1.12) EPS. As a group, analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $25,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares during the period. Sterling Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after buying an additional 2,867 shares during the period. Harbour Investments Inc. boosted its stake in shares of Intellia Therapeutics by 76.7% during the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after buying an additional 2,264 shares during the period. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 4th quarter valued at $40,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.